John Esther
Overview
Explore the profile of John Esther including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
9
Citations
140
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Patel S, Butler K, Esther J, Tuan J
Case Rep Oncol
. 2023 Feb;
16(1):45-48.
PMID: 36761367
Patients may present with multiple malignancies in the setting of particular environmental and occupational exposures. These patients often require combination systemic therapy, which has not yet been studied for concurrent...
2.
Swami U, Haaland B, Kessel A, Nussenzveig R, Maughan B, Esther J, et al.
J Urol
. 2020 Oct;
205(3):709-717.
PMID: 33080152
Purpose: Five programmed cell death protein 1 or its ligand (L1) inhibitors are approved for treatment of platinum refractory, locally advanced/unresectable or metastatic urothelial carcinoma. However, their comparative effectiveness is...
3.
Esther J, Dorff T, Maughan B
Cancer Treat Res Commun
. 2020 Jul;
24:100181.
PMID: 32673844
Non-metastatic castration resistant prostate cancer (nmCRPC) is defined as a disease state withlack of radiographic evidence of metastatic disease, a confirmed rising PSA level on continuous ADT and maintaining a...
4.
Swami U, Velho P, Nussenzveig R, Chipman J, Sacristan Santos V, Erickson S, et al.
Eur Urol
. 2020 Jul;
78(5):652-656.
PMID: 32624276
Recently, mutations in speckle-type pox virus and zinc finger protein (SPOP) gene (mutant SPOP [mtSPOP]) have been associated with improved outcomes to abiraterone in the castration-resistant setting. We hypothesized that...
5.
Khaki A, Li A, Diamantopoulos L, Bilen M, Santos V, Esther J, et al.
Cancer
. 2019 Dec;
126(6):1208-1216.
PMID: 31829450
Background: Immune checkpoint inhibitors (ICIs) represent an appealing treatment for patients with advanced urothelial cancer (aUC) and a poor performance status (PS). However, the benefit of ICIs for patients with...
6.
Hahn A, Klaassen Z, Agarwal N, Haaland B, Esther J, Ye X, et al.
Eur Urol Oncol
. 2019 Oct;
2(6):708-715.
PMID: 31588018
Context: No head-to-head clinical trials compare contemporary first-line therapies for metastatic renal cell carcinoma (mRCC). A network meta-analysis provides an approach for quantitative analysis. Objective: To indirectly compare the efficacy...
7.
Hahn A, Esther J, Haaland B, Swami U, Dizman N, Rathi N, et al.
J Geriatr Oncol
. 2019 Aug;
11(4):724-726.
PMID: 31402176
No abstract available.
8.
Esther J, Hale P, Hahn A, Agarwal N, Maughan B
Drugs Aging
. 2019 Feb;
36(5):395-401.
PMID: 30784023
Given the underrepresentation of older patients in registration trials for metastatic renal cell carcinoma (mRCC), data to support the use of any particular systemic therapy over others, based on age,...
9.
Esther J, Maughan B, Anderson N, Agarwal N, Hahn A
Curr Treat Options Oncol
. 2019 Feb;
20(2):14.
PMID: 30741354
Nonmetastatic castration-resistant prostate cancer (nmCRPC) comprises a relatively narrow niche of advanced prostate cancer, but the treatment landscape for men with nmCRPC has drastically changed over the past year. Prior...